Medication info
Terbinafine M Tablet (Terbinafine Hydrochloride)

Terbinafine M Tablet (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Mothers Pharma Co., Ltd.
Appearance
White to almost off-white round tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201308717 · Approved 2013.08.08 · Insurance code 622801550

Summary

Main use
Treatment of onychomycosis, cutaneous fungal infections (e.g., tinea pedis and tinea corporis), and tinea capitis
Who takes it
Adults · Children
Adult dose
Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment by condition is as follows: 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is generally given for 6 weeks~3 months. For infection of the fingernails or relatively small toes, or in younger patients, the treatment period may be shortened to 3 months or less. A 3-month treatment period is generally sufficient for toenail infections, but treatment may take 6 months or longer in some patients. The treatment period may be longer in patients with slow nail growth. For patients with creatinine clearance less than 50 mL/min, reduce the daily dose by 1/2.
Child dose
Administer to children 2 years of age and older. Use is not recommended in children under 2 years of age due to a lack of experience. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be administered regularly for the prescribed duration. Body weight less than 20 kg (under 5 years): Administer 62.5 mg once daily. Experience with use is limited; the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5 to 12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Ingredients

Manufacturer
Mothers Pharma Co., Ltd.

Efficacy & effects

Treatment of onychomycosis, cutaneous fungal infections (e.g., tinea pedis and tinea corporis), and tinea capitis

  • Skin fungal infections
  • athlete's foot
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used in adults for various skin fungal infections caused by dermatophytes such as athlete's foot, tinea corporis, and tinea cruris, as well as for onychomycosis. In children, it is used for the treatment of tinea capitis.

How to take

Adult dose

Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment by condition is as follows: 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is generally given for 6 weeks~3 months. For infection of the fingernails or relatively small toes, or in younger patients, the treatment period may be shortened to 3 months or less. A 3-month treatment period is generally sufficient for toenail infections, but treatment may take 6 months or longer in some patients. The treatment period may be longer in patients with slow nail growth. For patients with creatinine clearance less than 50 mL/min, reduce the daily dose by 1/2.

Child dose

Administer to children 2 years of age and older. Use is not recommended in children under 2 years of age due to a lack of experience. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be administered regularly for the prescribed duration. Body weight less than 20 kg (under 5 years): Administer 62.5 mg once daily. Experience with use is limited; the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5 to 12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Precautions

This medication is not recommended for patients with chronic or active liver disease. It is important to check for a history of liver disease and to perform regular liver function tests before and during treatment. If symptoms suggesting liver dysfunction or elevated test results are suspected, use of this medication should be discontinued immediately. This medication can cause serious liver damage, such as liver failure; hence, if signs of liver damage occur, treatment should be stopped immediately and professional examinations should be pursued. Patients with hypersensitivity to this medication, chronic liver disease, blood disorders, severe renal failure, lactating mothers, infants under 2 years of age, or specific hereditary metabolic disorders should not use this medication. Patients with impaired renal function, the elderly, underweight children, and those with skin conditions should use this medication with caution, and should discontinue immediately if serious skin reactions occur. This medication can cause various adverse reactions, particularly abnormal liver function, blood disorders, skin rashes, myalgia, gastrointestinal symptoms, and neurological symptoms, thus symptoms should be monitored closely. This medication should only be used for fungal infections that cannot be treated topically, and if dizziness or similar symptoms occur, it is advisable to avoid driving or operating machinery. This medication may interact with other drugs, thus if there are concomitant medications, it is essential to consult a doctor or pharmacist, as dose adjustments may be necessary. Women who are pregnant or are likely to become pregnant should weigh the risks and benefits carefully when administering this medication, and breastfeeding mothers should discontinue breastfeeding while on this medication. There is no experience administering this medication to children under 2 years of age, thus it is advisable not to administer it. Close observation of the physical condition is required when administering to children or the elderly. Overdose may lead to symptoms such as headache, nausea, abdominal pain, and dizziness, thus it is important to consult medical staff and receive appropriate treatment immediately. This medication should be kept out of reach of children, should not be transferred to other containers, and should be stored at room temperature away from sunlight.

Side effects

Liver failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, bullous dermatitis, psoriasiform rash, worsening of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial swelling, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, gastric discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, sensory abnormalities, sensory loss, decreased attention, insomnia, elevated BUN, pollakiuria, visual disturbance, tinnitus, anaphylactic reaction, angioedema, superficial erythema lupus, elevated serum total cholesterol, elevated triglyceride levels, malaise, tongue discoloration, palpitations, edema, menstrual abnormalities, paralysis, systemic dysfunction, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased eyesight, hearing loss, auditory dysfunction, vasculitis, permanent anosmia, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased blood creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture ingress. Additionally, it should be kept at a suitable room temperature between 1 degree and 30 degrees Celsius, avoiding extremes of heat and cold.

Appearance and packaging

Appearance

White to almost off-white round tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.